Galmed completes colon tissue assessment study
Galmed Pharmaceuticals (NASDAQ:GLMD) announced that its wholly owned subsidiary Colospan completed a first-in-human feasibility study of a colon tissue quality assessment platform in 32 colorectal cancer patients undergoing elective surgery.











